Zentalis Q1 2026 cash $211.8M; selects pivotal azenosertib dose; DENALI readout by year-end

Zentalis Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.50 vs consensus -$0.49 ▼ miss (-2.9%)

Cash, cash equivalents and marketable securities $211.8M as of March 31, 2026; provides runway into late 2027.
Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC based on DENALI Part 2a interim.
DENALI Part 2 topline readout expected by year-end 2026; potential accelerated approval pathway.
ASPENOVA Phase 3 confirmatory trial in Cyclin E1-positive PROC initiated with first patient dosed.
Q1 total operating expenses $37.9M, down from $45.6M (includes $7.8M non-recurring restructuring in prior year).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zentalis Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 12, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-26-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.